<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Noonan syndrome genes: Frequency estimate and genotype-phenotype correlation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Noonan syndrome genes: Frequency estimate and genotype-phenotype correlation</h1>
<div class="graphic"><div class="figure"><div class="ttl">Noonan syndrome genes: Frequency estimate and genotype-phenotype correlation</div><div class="cntnt"><table cellspacing="0"><colgroup width="10%"></colgroup><colgroup width="20%"></colgroup><colgroup width="10%"></colgroup><colgroup width="60%"></colgroup> <tbody> <tr> <td class="subtitle1">Gene</td> <td class="subtitle1">Phenotype</td> <td class="subtitle1">Percent<sup>[1]</sup></td> <td class="subtitle1">Genotype-phenotype correlation</td> </tr> <tr> <td rowspan="3"><em>PTPN11</em></td> <td>NS</td> <td class="centered">50</td> <td>Classical NS. Highest incidence of pulmonary valve stenosis, atrial septal defects.</td> </tr> <tr> <td>NS with increased risk of JMML</td> <td class="centered"> </td> <td>Specific mutations.</td> </tr> <tr> <td>NSML</td> <td class="centered"> </td> <td>Specific mutations. Usually normal intellect.</td> </tr> <tr> <td><em>SOS1</em><sup>[2]</sup></td> <td>NS</td> <td class="centered">11</td> <td>Less short stature and intellectual disability. Dry skin common.</td> </tr> <tr> <td><em>SOS2</em></td> <td>Classical NS</td> <td class="centered"> </td> <td>Similar to <em>SOS1</em> phenotype, but lymphatic anomalies may be prevalent.</td> </tr> <tr> <td><em>RAF1</em><sup>[3]</sup></td> <td>NS, but variable</td> <td class="centered">5</td> <td>Hypertrophic cardiomyopathy common (95%); may be neonatal. Pediatric dilated cardiomyopathy. Pulmonary artery hypertension. Lentigines (NSML) reported.</td> </tr> <tr> <td><em>RIT1</em><sup>[4]</sup></td> <td>NS, but variable</td> <td class="centered">5</td> <td>Normal growth, skin, and intellect. High incidence of cardiac abnormalities, including atrial tachyarrhythmia. Hypertrophic cardiomyopathy common; may be neonatal. Lymphatic complications common, including prenatal. May have small increased malignancy risk.</td> </tr> <tr> <td><em>LZTR1</em><sup>[5] </sup></td> <td>NS, variable from mild to lethal fetal hydrops</td> <td class="centered">10 </td> <td>Lymphatic anomalies and hypertrophic cardiomyopathy prevalent amongst individuals with autosomal-recessive <em>LZTR1</em>-associated NS. Autosomal-dominant forms are frequently milder.</td> </tr> <tr> <td><em>NRAS</em><sup>[6]</sup></td> <td>Classical NS</td> <td class="centered">0.2</td> <td> </td> </tr> <tr> <td><em>RRAS, RRAS2</em></td> <td>Classical NS</td> <td class="centered"> </td> <td> </td> </tr> <tr> <td><em>MRAS</em></td> <td>NS</td> <td class="centered"> </td> <td>Hypertrophic cardiomyopathy.</td> </tr> <tr> <td><em>SHOC2</em><sup>[7]</sup></td> <td>NS with loose anagen hair</td> <td class="centered">2</td> <td>Sparse hair, hyperpigmented skin, eczema, keratosis pilaris. Nasal voice. Growth hormone deficiency common.</td> </tr> <tr> <td><em>CBL</em><sup>[8]</sup></td> <td>NS, but variable, often subtle manifestations</td> <td class="centered"> </td> <td>Increased risk of JMML. Moyamoya disease reported.</td> </tr> <tr> <td><em>PPP1CB</em><sup>[9]</sup></td> <td><em>SHOC2-</em>like</td> <td class="centered"> </td> <td> </td> </tr> <tr> <td><em>KRAS</em></td> <td>Some NS/CFC</td> <td class="centered">1.5</td> <td>Intellectual disability more common.</td> </tr> <tr> <td><em>BRAF</em></td> <td>Some NS/CFC</td> <td class="centered">&lt;2</td> <td>Skin and hair differences more common. More intellectual disability. NSML reported.</td> </tr> <tr> <td><em>MAP2K1</em></td> <td>Rare NS/CFC</td> <td class="centered">&lt;2</td> <td> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><em>PTPN11</em>: protein tyrosine phosphatase, nonreceptor type 11; NS: Noonan syndrome; JMML: juvenile myelomonocytic leukemia; NSML: Noonan syndrome with multiple lentigines; <em>SOS1</em>: SOS Ras/Rac guanine nucleotide exchange factor 1; <em>SOS2</em>: SOS Ras/Rho guanine nucleotide exchange factor 2; <em>RAF1</em>: Raf-1 proto-oncogene, serine/threonine kinase; <em>RIT1</em>: Ric-like protein without CAAX motif 1; <em>LZTR1</em>: leucine zipper-like transcription regulator 1; <em>NRAS</em>: NRAS proto-oncogene, GTPase; <em>RRAS</em>: related RAS viral oncogene homolog; <em>MRAS</em>: muscle RAS viral oncogene homolog; <em>SHOC2</em>: SHOC2, leucine rich repeat scaffold protein; <em>CBL</em>: Cbl proto-oncogene; <em>PPP1CB</em>: protein phosphatase 1 catalytic subunit beta; <em>KRAS</em>: KRAS proto-oncogene, GTPase; CFC: cardio-facio-cutaneous syndrome; <em>BRAF</em>: B-Raf proto-oncogene, serine/threonine kinase; <em>MAP2K1</em>: mitogen-activated protein kinase kinase 1.</div><div class="graphic_reference">References: 

<ol>
<li>Aoki Y, Niihori T, Inoue S, Matsubara Y. Recent advances in RASopathies. J Hum Genet 2016; 61:33.</li>
<li>Lepri F, De Luca A, Stella L, et al. SOS1 mutations in Noonan syndrome: Molecular spectrum, structural insights on pathogenic effects, and genotype–phenotype correlations. Hum Mutat 2011; 32:760.</li>
<li>Razzaque MA, Nishizawa T, Komoike Y, et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 2007; 39:1013.</li>
<li>Bertola DR, Yamamoto GL, Almeida TF, et al. Further evidence of the importance of RIT1 in Noonan syndrome. Am J Med Genet A 2014; 164A:2952.</li>
<li class="">Johnston JJ, van der Smagt JJ, Rosenfeld JA, et al. Autosomal recessive Noonan syndrome associated with biallelic LZTR1 variants. Genet Med 2018; 20:1175</li>
<li>Altmüller F, Lissewski C, Bertola D, et al. Genotype and phenotype spectrum of NRAS germline variants. Eur J Hum Genet 2017; 25:823.</li>
<li>Gripp KW, Zand DJ, Demmer L, et al. Expanding the SHOC2 mutation associated phenotype of Noonan syndrome with loose anagen hair: Structural brain anomalies and myelofibrosis. Am J Med Genet A 2013; 161A:2420.</li>
<li>Martinelli S, De Luca A, Stellacci E, et al. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet 2010; 87:250.</li>
<li>Gripp KW, Aldinger KA, Bennett JT, et al. A novel rasopathy caused by recurrent de novo missense mutations in PPP1CB closely resembles Noonan syndrome with loose anagen hair. Am J Med Genet A 2016; 170:2237.</li></ol></div><div id="graphicVersion">Graphic 117465 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
